Sou Hu Cai Jing·2025-10-24 08:29Group 1 - The core viewpoint of the article is that China Galaxy has given a "recommended" rating to Dongshan Precision (002384.SZ) based on its stable revenue growth and ongoing merger and acquisition activities [1] - Dongshan Precision's revenue has shown steady growth, although the net profit attributable to the parent company in Q3 was affected by mergers, acquisitions, and the launch of new factories [1] - The company is progressing smoothly with its merger and acquisition activities and is planning to issue H-shares for listing [1] Group 2 - The article highlights the booming secondary market for biomedicine, with overseas licensing deals in the sector reaching $80 billion this year [1] - There is a contrast noted between the hot secondary market and the cooling fundraising environment in the primary market for biomedicine [1]